TABLE 5.
Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With >12 Months Versus ≤12 Months of Clopidogrel After Percutaneous Coronary Revascularization With DES*
| Univariate
|
Multivariable Adjusted†
|
Propensity Adjusted‡
|
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| DM treated with insulin | ||||||
| Death | 0.51§ | 0.33–0.77 | 0.50§ | 0.32–0.76 | 0.53§ | 0.35–0.81 |
| Death or MI | 0.60‖ | 0.42–0.86 | 0.61‖ | 0.43–0.88 | 0.63‖ | 0.44–0.91 |
| CABG or PCI | 0.92 | 0.57–1.50 | 0.93 | 0.57–1.51 | 0.96 | 0.58–1.56 |
| Stroke | 0.75 | 0.15–3.74 | 0.76 | 0.15–3.85 | 0.77 | 0.15–3.87 |
| Severe bleed | 0.31‖ | 0.13–0.76 | 0.29‖ | 0.12–0.70 | 0.42 | 0.17–1.03 |
|
| ||||||
| DM, no insulin | ||||||
| Death | 0.57§ | 0.43–0.75 | 0.56§ | 0.42–0.74 | 0.62§ | 0.46–0.82 |
| Death or MI | 0.62§ | 0.50–0.77 | 0.60§ | 0.48–0.75 | 0.64§ | 0.52–0.80 |
| CABG or PCI | 0.81 | 0.64–1.03 | 0.82 | 0.65–1.04 | 0.84 | 0.66–1.06 |
| Stroke | 0.72 | 0.33–1.55 | 0.78 | 0.36–1.69 | 0.85 | 0.39–1.86 |
| Severe bleed | 1.24 | 0.63–2.44 | 1.26 | 0.64–2.49 | 1.63 | 0.82–3.22 |
|
| ||||||
| No diabetes mellitus | ||||||
| Death | 0.98 | 0.76–1.25 | 0.98 | 0.77–1.26 | 1.02 | 0.80–1.31 |
| Death or MI | 0.85 | 0.70–1.03 | 0.85 | 0.70–1.03 | 0.89 | 0.73–1.08 |
| CABG or PCI | 1.00 | 0.81–1.23 | 1.02 | 0.83–1.26 | 1.05 | 0.85–1.30 |
| Stroke | 0.82 | 0.38–1.77 | 0.83 | 0.38–1.81 | 0.87 | 0.40–1.89 |
| Severe bleed | 0.97 | 0.56–1.69 | 0.96 | 0.55–1.66 | 1.41 | 0.81–2.47 |
*
Subjects with any adverse events in the first year were excluded.
†
Adjusted for age, year of stenting, smoking, acute coronary syndrome during index admission, hypertension, peripheral vascular disease, heart failure, chronic kidney disease, and warfarin at discharge.
‡
Adjusted for the propensity to use clopidogrel for >12 months.
§
p < 0.001.
‖
p < 0.01.